COVID-19 vaccine: BioNTech and Pfizer report 90% effectiveness in trials
Germany’s BioNTech and its US pharma partner Pfizer announced on Monday that their vaccine candidate is more than 90% effective in preventing COVID-19 in a trial of over 43,000 participants.
“Today is a great day for science and humanity,“ said Dr Albert Bourla, chairman and CEO of Pfizer in a statement. “The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19.”
Based on current projections from the company, it expects to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.
Bourla said that they are “reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen”.
You may be interested
Greek Archbishop Ieronymos: Islam is not a religion but a political ideology of conquestPanos - Jan 18, 2021
Archbishop of Athens and All Greece Ieronymos II expressed the view that Islam and its citizens, was not a religion,…
Nikos Dendias: Only matters Greece will discuss with Turkey is EOZ and sea-shelfPanos - Jan 18, 2021
Foreign Affairs Minister Nikos Dendias made it clear that the only issue Greece would discuss with Turkey in the upcoming exploratory…
Video – This is the upgraded F-16 Viper of the Hellenic Air ForcePanos - Jan 18, 2021
The latest variant of the F-16 Fighting Falcon fourth-generation, the F-16V or Viper made its maiden flight at the Tanagra air base…